| Mr Brian R Theroux, PA | |
|
1672 S County Trl, Ste 101, E Greenwich, RI 02818-5098 | |
| (401) 885-7546 | |
| (401) 885-6658 |
| Full Name | Mr Brian R Theroux |
|---|---|
| Gender | Male |
| Speciality | Physician Assistant |
| Experience | 22 Years |
| Location | 1672 S County Trl, E Greenwich, Rhode Island |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275546277 | NPI | - | NPPES |
| DE76182 | Medicaid | RI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363AM0700X | Physician Assistant - Medical | PA00289 (Rhode Island) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Miriam Hospital | Providence, RI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dermatology Professionals Inc | 9234283953 | 16 |
| Dermatology Professionals Llc | 1254653355 | 8 |
News Archive
TxCell SA, a biotechnology company developing innovative, economically viable, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that TxCell researchers have achieved positive results for Col-Treg, its second product candidate from its ASTrIA platform, in a model of autoimmune uveitis, a leading cause of blindness with very limited treatment options.
Tobacco use is the leading cause of preventable death and disability in the U.S., while heavy drinking ranks as the third leading cause of preventable death. Cigarette taxation has been recognized as one of the most significant policy instruments to reduce smoking.
New IMBRUVICA (ibrutinib) Phase II data announced by Pharmacyclics, Inc. today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL).
Children with cerebral palsy frequently undergo invasive surgeries - lengthening tendons, rotating bones, transferring muscles to new locations - in hopes of improving their physical ability to walk or move.
Individuals with colorectal cancer that has metastasized to the liver or lung live longer after curative surgery plus chemotherapy than their counterparts who receive palliative chemotherapy alone, report researchers.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Brian R Theroux, PA 1672 S County Trl, Ste. 301, E Greenwich, RI 02818-5098 Ph: (401) 885-7546 | Mr Brian R Theroux, PA 1672 S County Trl, Ste 101, E Greenwich, RI 02818-5098 Ph: (401) 885-7546 |
News Archive
TxCell SA, a biotechnology company developing innovative, economically viable, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that TxCell researchers have achieved positive results for Col-Treg, its second product candidate from its ASTrIA platform, in a model of autoimmune uveitis, a leading cause of blindness with very limited treatment options.
Tobacco use is the leading cause of preventable death and disability in the U.S., while heavy drinking ranks as the third leading cause of preventable death. Cigarette taxation has been recognized as one of the most significant policy instruments to reduce smoking.
New IMBRUVICA (ibrutinib) Phase II data announced by Pharmacyclics, Inc. today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL).
Children with cerebral palsy frequently undergo invasive surgeries - lengthening tendons, rotating bones, transferring muscles to new locations - in hopes of improving their physical ability to walk or move.
Individuals with colorectal cancer that has metastasized to the liver or lung live longer after curative surgery plus chemotherapy than their counterparts who receive palliative chemotherapy alone, report researchers.
› Verified 6 days ago